Use este identificador para citar ou linkar para este item: https://www.arca.fiocruz.br/handle/icict/37932

Tipo de documento
Artigo
Direito Autoral
Acesso restrito
Coleções
Compartilhar

Estatísticas
Metadata
Mostrar registro completo

LIPID MEDIATORS OF INFLAMMATION AND RESOLUTION IN INDIVIDUALS WITH TUBERCULOSIS AND TUBERCULOSIS-DIABETES
Shivakoti, Rupak et al. | Data do documento: 2020
Autor(es)
Shivakoti, Rupak
Dalli, Jesmond
Kadam, Dileep
Gaikwad, Sanjay
Barthwal, Madhusudan
Colas, Romain A.
Mazzacuva, Francesca
Lokhande, Rahul
Dharmshale, Sujata
Bharadwaj, Renu
Kagal, Anju
Pradhan, Neeta
Deshmukh, Sona
Atre, Sachin
Sahasrabudhe, Tushar
Kakrani, Arjun
Kulkarni, Vandana
Raskar, Swapnil
Suryavanshi, Nishi
Chon, Sandy
Gupte, Akshay
Gupta, Amita
Gupte, Nikhil
Arriaga Gutiérrez, María Belen
Fukutani, Kiyoshi Ferreira
Andrade, Bruno de Bezerril
Golub, Jonathan E.
Mave, Vidya
Afiliação
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA / Columbia University Mailman School of Public Health. New York, NY, USA.
Queens Mary University of London. William Harvey Research Institute. London, UK.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
Hospital & Research Centre. D.Y. Patil Medical College. D.Y. Patil Vidyapeeth. Pune, India.
Queens Mary University of London. William Harvey Research Institute. London, UK.
Queens Mary University of London. William Harvey Research Institute. London, UK.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India / Byramjee-Jeejeebhoy Government Medical College. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
Hospital & Research Centre. D.Y. Patil Medical College. D.Y. Patil Vidyapeeth. Pune, India.
Hospital & Research Centre. D.Y. Patil Medical College. D.Y. Patil Vidyapeeth. Pune, India.
Hospital & Research Centre. D.Y. Patil Medical College. D.Y. Patil Vidyapeeth. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA / University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA / University Clinical Research Site. Byramjee-Jeejeebhoy Medical College-Johns Hopkins. Pune, India.
Fundação Oswaldo Cruz, Instituto Goncalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil / Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil.
Fundação Oswaldo Cruz, Instituto Goncalo Moniz. Salvador, BA, Brasil / Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Curso de Medicina. Salvador, BA, Brasil.
Fundação Oswaldo Cruz, Instituto Goncalo Moniz. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina. Salvador, BA, Brasil / Fundação José Silveira. Multinational Organization Network Sponsoring Translational and Epidemiological Research. Salvador, BA, Brazil / Faculdade de Tecnologia e Ciências. Curso de Medicina. Salvador, BA, Brasil / Universidade Salvador. Laureate Universities. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA / Johns Hopkins Bloomberg School of Public Health. Baltimore, Maryland, USA / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil.
Johns Hopkins University. School of Medicine. Baltimore, Maryland, USA / Hospital & Research Centre. D.Y. Patil Medical College. D.Y. Patil Vidyapeeth. Pune, India / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil.
Resumo em Inglês
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution of inflammation) lipid mediators in individuals with TB and TB-DM. A nested cross-sectional study of 40 individuals (20 newly diagnosed DM and 20 without DM) was conducted within a cohort of individuals with active drug-susceptible treatment-naïve pulmonary TB. Lipid mediators were quantified in serum samples through lipid mediator profiling. We conducted correlation-based analysis of these mediators. Overall, the arachidonic acid-derived leukotriene and prostaglandin families were the most abundant pro-inflammatory lipid mediators, while lipoxins and maresins families were the most abundant pro-resolving lipid mediators in individuals with TB and TB-DM. Individuals with TB-DM had increased correlations and connectivity with both pro-inflammatory and pro-resolving lipid mediators compared to those with TB alone. We identified the most abundant lipid mediator metabolomes in circulation among individuals with TB and TB-DM; in addition, our data shows a substantial number of significant correlations between both pro-inflammatory and pro-resolving lipid mediators in individuals with TB-DM, delineating a molecular balance that potentially defines this comorbidity.
Palavras-chave
Tuberculose
Diabetes
Lipídios
Inflamação
Mediadores especializados em resolução de problemas
Prostaglandinas
Leucotrienos
Lipoxinas
Resolvinas
 
Palavras-chave em inglês
Tuberculosis
Diabetes
Lipids
Inflammation
Specialized pro-resolving mediators
Prostaglandins
Leukotrienes
Lipoxins
Resolvins
 
Editor
Elsevier
Referência
SHIVAKOTI, Rupak et al. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes. Prostaglandins and Other Lipid Mediators, v. 147, p. 1-9, 2020.
DOI
10.1016/j.prostaglandins.2019.106398
ISSN
1098-8823